← board
IFRX
distress 3/10 · well-funded / low risk$1.79-1%today-35% from 52w high
Revenue
pre-revenue
Liquidity
$40M
Runway
1.1 yrs
Shares 1y
0%
Price & events
+73.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-6.3%
1W
-7.3%
1M
+14.7%
3M
+77.2%
6M
+108.4%
1Y
+23.4%
2Y
-33.2%
5Y
-65.2%
All
Overview
- Market Cap
- $129.40M
- Volume
- 82.82K
- 52 Week Range
- $0.80 – $2.74
- Total Shares
- 72.29M
- Float Shares
- 55.47M
- Short %
- 6.01%
- % Held by Insiders
- 2.95%
- % Held by Institutions
- 30.29%
- RVOL
- 0.07x
- Beta
- 2.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+338% upside) · 7 analysts
- 2026-05-13Raymond JamesOutperform → Strong Buy
- 2026-05-11Cantor FitzgeraldOverweight
- 2026-05-11HC Wainwright & Co.Buy
- 2026-04-21GuggenheimBuy
- 2026-03-20GuggenheimBuy
- 2025-12-30HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-18InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key Support - Algorithmic Stock Picks - dars.gov.et
- 2026-07-17IFRX Stock Price, Quote & Chart - ChartMill
- 2026-07-11IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock Eases - Earnings Call Q&A - DonanımHaber
- 2026-07-06InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support Level - ETF Premium Discount - DonanımHaber
- 2026-07-05Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
- 2026-06-30InflaRx Assessing Feasibility of Broadened Strategy for - GlobeNewswire
- 2026-06-30InflaRx Assessing Feasibility of Broadened Strategy for - GlobeNewswire
- 2026-06-30InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.